Published in Nature on January 10, 2000
Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J Virol (2005) 4.01
Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer (2010) 3.55
Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest (2004) 3.39
Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog (2007) 3.16
Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev (2003) 2.90
Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol (2001) 2.87
BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer (2012) 2.80
Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J Virol (2002) 2.71
Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer (2010) 2.68
KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest (2010) 2.55
DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.41
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J Virol (2002) 2.32
Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol (2001) 2.31
Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J Virol (2002) 2.28
Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes. J Virol (2001) 2.25
Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol (2001) 2.21
Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 2.19
Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. J Virol (2000) 2.17
Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol (2003) 2.07
Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies. J Virol (2000) 1.96
Differential regulation of the overlapping Kaposi's sarcoma-associated herpesvirus vGCR (orf74) and LANA (orf73) promoters. J Virol (2001) 1.84
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood (2006) 1.83
Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus. J Virol (2005) 1.74
EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog (2006) 1.71
Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe (2010) 1.70
Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci U S A (2003) 1.69
Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci (2001) 1.65
Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol (2004) 1.64
A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest. J Virol (2010) 1.64
Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci (2001) 1.64
Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol (2006) 1.63
The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta. J Virol (2003) 1.62
Mechanisms governing expression of the v-FLIP gene of Kaposi's sarcoma-associated herpesvirus. J Virol (2001) 1.56
Lytic but not latent infection by Kaposi's sarcoma-associated herpesvirus requires host CSL protein, the mediator of Notch signaling. Proc Natl Acad Sci U S A (2003) 1.54
Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett (2009) 1.54
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood (2008) 1.52
Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci U S A (2004) 1.52
Transcripts encoding K12, v-FLIP, v-cyclin, and the microRNA cluster of Kaposi's sarcoma-associated herpesvirus originate from a common promoter. J Virol (2005) 1.50
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest (2007) 1.49
Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis. PLoS Pathog (2007) 1.48
Viruses associated with human cancer. Biochim Biophys Acta (2007) 1.47
Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res (2007) 1.47
Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency. J Virol (2005) 1.47
The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol (2002) 1.45
Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. Proc Natl Acad Sci U S A (2006) 1.43
Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe (2014) 1.42
HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis (2008) 1.42
Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J Virol (2010) 1.42
Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology (2008) 1.41
Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett (2011) 1.41
Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist (2011) 1.40
Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol (2007) 1.39
Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol (2006) 1.36
The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol (2007) 1.36
Internal ribosome entry site regulates translation of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein. J Virol (2001) 1.34
Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. J Virol (2004) 1.34
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol (2006) 1.32
Latently expressed human herpesvirus 8-encoded interferon regulatory factor 2 inhibits double-stranded RNA-activated protein kinase. J Virol (2001) 1.31
Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions. J Virol (2006) 1.30
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells. J Virol (2003) 1.28
The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest (2006) 1.26
Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production. J Virol (2004) 1.26
Activation of the Kaposi's sarcoma-associated herpesvirus major latency locus by the lytic switch protein RTA (ORF50). J Virol (2005) 1.24
The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters. J Virol (2001) 1.24
Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood (2013) 1.23
Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif. J Virol (2004) 1.21
Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol (2001) 1.21
Kaposi's sarcoma-associated herpesvirus induction of chromosome instability in primary human endothelial cells. Cancer Res (2004) 1.19
A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. J Virol (2007) 1.19
An Sp1 response element in the Kaposi's sarcoma-associated herpesvirus open reading frame 50 promoter mediates lytic cycle induction by butyrate. J Virol (2005) 1.19
Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology (2009) 1.18
Cell cycle regulation by Kaposi's sarcoma-associated herpesvirus K-bZIP: direct interaction with cyclin-CDK2 and induction of G1 growth arrest. J Virol (2003) 1.16
Kaposi's sarcoma-associated herpesvirus RTA promotes degradation of the Hey1 repressor protein through the ubiquitin proteasome pathway. J Virol (2009) 1.15
Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. Virology (2007) 1.14
Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol (2007) 1.14
The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency. Future Microbiol (2011) 1.13
Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces expression of the helix-loop-helix protein Id-1 in human endothelial cells. J Virol (2003) 1.11
Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest (2005) 1.11
Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis. J Clin Microbiol (2006) 1.10
Determination of Kaposi's sarcoma-associated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding. J Virol (2007) 1.09
Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res (2010) 1.09
The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood (2005) 1.08
ORF73 of herpesvirus Saimiri strain C488 tethers the viral genome to metaphase chromosomes and binds to cis-acting DNA sequences in the terminal repeats. J Virol (2003) 1.07
Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas. J Virol (2010) 1.07
The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5. J Biol Chem (2009) 1.06
Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA. J Virol (2012) 1.05
Poly(ADP-ribose) polymerase 1 binds to Kaposi's sarcoma-associated herpesvirus (KSHV) terminal repeat sequence and modulates KSHV replication in latency. J Virol (2004) 1.05
The Herpesvirus Saimiri open reading frame 73 gene product interacts with the cellular protein p32. J Virol (2002) 1.05
Proteomic analysis of the Kaposi's sarcoma-associated herpesvirus terminal repeat element binding proteins. J Virol (2006) 1.04
Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A (1989) 11.76
Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32
HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature (1988) 7.35
Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature (1989) 5.76
Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. Nature (1991) 5.07
Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science (1997) 4.37
Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med (2000) 4.36
Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science (1998) 4.24
Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. N Engl J Med (1997) 3.90
A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J (1993) 3.74
Immunization for Ebola virus infection. Nat Med (1998) 3.27
Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med (2001) 3.11
Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol (1998) 2.99
Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science (1994) 2.79
Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci U S A (1992) 2.72
Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science (1990) 2.63
The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci (2002) 2.61
A cloned MCGF cDNA encodes a multilineage hematopoietic growth factor: multiple activities of interleukin 3. J Immunol (1985) 2.56
cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1. Mol Cell Biol (1992) 2.55
Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J (1996) 2.55
Regulation of the proinflammatory effects of Fas ligand (CD95L). Science (1998) 2.43
Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science (1990) 2.33
An interaction between the DNA-binding domains of RelA(p65) and Sp1 mediates human immunodeficiency virus gene activation. Mol Cell Biol (1994) 2.26
Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol (2001) 2.12
A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol Chem (1999) 2.06
Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). Mol Cell Biol (1993) 2.00
Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science (1989) 1.95
Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med (1992) 1.93
The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med (1995) 1.90
The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function. J Biol Chem (2001) 1.88
Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J Virol (1998) 1.85
Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science (1995) 1.77
Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J Virol (1991) 1.74
Regulation of human flap endonuclease-1 activity by acetylation through the transcriptional coactivator p300. Mol Cell (2001) 1.70
Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A (1997) 1.69
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66
Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation (2000) 1.65
Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-kappa B subunits in endothelial and epithelial cells. Mol Cell Biol (1993) 1.62
Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther (1995) 1.60
Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature (1993) 1.58
Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther (1999) 1.57
Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300. EMBO J (1998) 1.56
Transcription coactivator p300 binds PCNA and may have a role in DNA repair synthesis. Nature (2001) 1.55
Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol Med (1999) 1.53
Transcriptional regulation of NF-kappa B2: evidence for kappa B-mediated positive and negative autoregulation. Mol Cell Biol (1994) 1.51
A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription. Mol Cell Biol (1997) 1.50
Proteinase-activated receptor-2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. Exp Dermatol (1999) 1.45
Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci U S A (1996) 1.44
Ratiometry of transmembrane voltage-sensitive fluorescent dye emission in hearts. Am J Physiol Heart Circ Physiol (2000) 1.42
Regulation of beta -catenin transformation by the p300 transcriptional coactivator. Proc Natl Acad Sci U S A (2000) 1.41
Vaccines for the prevention of HIV-1 disease. Curr Opin Immunol (2001) 1.41
A novel Ets-related transcription factor, Elf-1, binds to human immunodeficiency virus type 2 regulatory elements that are required for inducible trans activation in T cells. J Virol (1992) 1.38
Differential regulation of human immunodeficiency viruses (HIVs): a specific regulatory element in HIV-2 responds to stimulation of the T-cell antigen receptor. Proc Natl Acad Sci U S A (1990) 1.37
Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci U S A (1993) 1.36
HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator. Proc Natl Acad Sci U S A (1998) 1.35
Specific NF-kappa B subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J Virol (1992) 1.34
A combined finite element and optimization investigation of lumbar spine mechanics with and without muscles. Spine (Phila Pa 1976) (1993) 1.33
Recombinant platelet-derived growth factor B gene expression in porcine arteries induce intimal hyperplasia in vivo. J Clin Invest (1993) 1.33
CIPER, a novel NF kappaB-activating protein containing a caspase recruitment domain with homology to Herpesvirus-2 protein E10. J Biol Chem (1999) 1.32
Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci U S A (1996) 1.30
Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience (2007) 1.30
Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res (1998) 1.30
The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Nat Med (1997) 1.30
Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther (1992) 1.28
Gene transfer into normal and atherosclerotic human blood vessels. Circ Res (1998) 1.24
NF-kappa B-mediated activation of the human immunodeficiency virus enhancer: site of transcriptional initiation is independent of the TATA box. J Virol (1989) 1.22
Differential regulation of NF-kappaB2(p100) processing and control by amino-terminal sequences. Mol Cell Biol (1996) 1.21
Waiting times for cancer surgery in Ontario: 1984-2000. Clin Oncol (R Coll Radiol) (2006) 1.20
Activation of the human immunodeficiency virus type 2 enhancer is dependent on purine box and kappa B regulatory elements. J Virol (1992) 1.17
Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A (1998) 1.17
HIV-1 reverse transcriptase and integrase enzymes physically interact and inhibit each other. FEBS Lett (2001) 1.17
Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther (1992) 1.15
Specificity of cyclin E-Cdk2, TFIIB, and E1A interactions with a common domain of the p300 coactivator. Mol Cell Biol (1999) 1.13
Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci U S A (1994) 1.12
Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Proc Natl Acad Sci U S A (1992) 1.12
Basolateral proteinase-activated receptor (PAR-2) induces chloride secretion in M-1 mouse renal cortical collecting duct cells. J Physiol (1999) 1.12
A direct interaction between proliferating cell nuclear antigen (PCNA) and Cdk2 targets PCNA-interacting proteins for phosphorylation. J Biol Chem (2000) 1.11
Inhibition of the alloantibody response by CD95 ligand. Nat Med (1997) 1.10
Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells. Gene Ther (1994) 1.10
Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol (2001) 1.10
Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils. J Immunol (2000) 1.07
The cytoplasmic domain of the interleukin-1 receptor is required for nuclear factor-kappa B signal transduction. J Biol Chem (1994) 1.06
Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals. J Virol (1993) 1.05
Transcription factor AP-2 regulates human immunodeficiency virus type 1 gene expression. J Virol (1994) 1.05
Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol (2012) 1.05
Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor confers resistance to the antiproliferative effect of interferon-alpha. Mol Med (1998) 1.04
Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-kappa B in vivo. Mol Cell Biol (1993) 1.03
Cancellous bone Young's modulus variation within the vertebral body of a ligamentous lumbar spine--application of bone adaptive remodeling concepts. J Biomech Eng (1995) 1.02
Proposed NF-kappa B/I kappa B family nomenclature. Genes Dev (1993) 1.02
Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study. Curr Oncol (2013) 1.02
Mechanisms of tumor-induced immunosuppression: evidence for contact-dependent T cell suppression by monocytes. Mol Med (1996) 1.00
Introduction of vascular smooth muscle cells expressing recombinant genes in vivo. Circulation (1991) 1.00
Tumor necrosis factor-alpha, interleukin 1, and phorbol myristate acetate are independent activators of NF-kappa B which differentially activate T cells. Cytokine (1991) 1.00
Activation of the human immunodeficiency virus type 1 enhancer is not dependent on NFAT-1. J Virol (1992) 1.00
Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction. J Biol Chem (1994) 1.00
Regulation of the IL-2 receptor alpha-gene. Interaction of a kappa B binding protein with cell-specific transcription factors. J Immunol (1989) 0.98